Does glucose in dialysis fluid protect erythrocytes in patients with chronic renal failure?

Blood Purif. 2007;25(5-6):422-9. doi: 10.1159/000109817. Epub 2007 Oct 15.

Abstract

Background/aims: The aim of this study was to assess the multifaceted influence of glucose present in dialyzing fluid on erythrocytes of patients with chronic renal failure (CRF) undergoing regular hemodialysis.

Methods: A group of 44 subjects with CRF undergoing regular hemodialysis was studied. Two tests were used: osmotic fragility and resistance to the hemolytic agent saponin. The total content of isoprostane 8-iso-prostaglandin F2alpha type III (8-iPF2alpha-III) in plasma and erythrocyte's membrane were determined by the ELISA method.

Results: The presence of glucose in the dialysate is associated with lower intravascular hemolysis markers and high total 8-iPF2alpha-III concentrations in plasma.

Conclusion: The presence of glucose in dialyzing fluid could protect erythrocytes. It limits hemolysis in patients with CRF, but, on the other hand, increases the oxidative processes. This kind of treatment along with other therapeutic intervention such as administration of antioxidants (e.g. alpha-tocopherol, ascorbic acid, N-acetylcysteine) could improve the condition of erythrocytes and outcome in CRF.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Erythrocytes / drug effects*
  • Female
  • Glucose / pharmacology*
  • Glucose / therapeutic use
  • Hemodialysis Solutions / chemistry*
  • Hemodialysis Solutions / pharmacology
  • Hemolysis / drug effects
  • Humans
  • Isoprostanes / blood
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / therapy*
  • Male
  • Middle Aged
  • Osmotic Fragility / drug effects
  • Oxidative Stress
  • Renal Dialysis / methods
  • Saponins / pharmacology

Substances

  • Hemodialysis Solutions
  • Isoprostanes
  • Saponins
  • isoprostane F2alpha III
  • Glucose